Oncology

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses whether the treatment emergent adverse events (AEs) were consistent with the known safety profiles for belantamab mafodotin and pomalidomide.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses common adverse events (AEs) observed in patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the interim analysis of the OPTIC trial demonstrated in terms of the safety and arterial occlusive events profiles with response-based ponatinib dosing regimens.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the common prior therapies for patients with relapsed/refractory multiple myeloma who were enrolled in the ALGONQUIN trial.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the PACE trial was able to demonstrate in regard to patient response to ponatinib for patients with resistant and intolerant chronic-phase CML with substantial prior second-generation treatment.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the dose limiting toxicities observed among patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.

ET and CT are used as standard maintenance therapy for HR-positive and HER-negative MBC in clinical practice, and there was no prospective study data on which is better, according to the study authors.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses the reasons that the use of second-generation tyrosine kinase inhibitors in patients with chronic-phase CML who have failed one or more second-generation tyrosine kinase inhibitors needed further investigation.

Helen Thackray, MD, provides a brief overview and highlights of the RESET clinical trial.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the response rates and survival outcomes were for ponatinib among patients who failed second-generation tyrosine kinase inhibitors in the OPTIC trial.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the implications of the results of his research on further investigation and treatment opportunities for patients with polycythemia vera.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the noteworthy results observed in the study in relation to cause of death among patients with polycythemia vera.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the issues existing around prior data on the causes of death for patients with polycythemia vera (PV) and why it was important to have greater clarity in this area.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the common treatments for patients with polycythemia vera.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the survival estimates for patients with polycythemia vera in the past and the mortality rates among these patients.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on what polycythemia vera (PV) is and why it was important to understand mortality and causes of death among patients with PV.

New research identifies patients most at risk of continuing problems with medulloblastoma, which can be applied immediately in medical clinics.

Study indicates pure CBD was able to reduce cell viability in 3 of the 6 cell lines and that this effect was cell line specific rather than specific to certain cancers.

Targeted therapies often have better toxicity profiles, allowing patients to remain adherent and stay on medications longer.

FDA approves Gallium 68 PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.

Patients with relapsed/refractory leukemia and lymphomas generally have a grim prognosis, which has paved the way for immunotherapy treatments.

Further, the findings suggest that cancer survivors are also likely to be at an increased risk of severe coronavirus disease 2019 (COVID-19) outcomes, given that both influenza and COVID-19 are both epidemic respiratory viruses.

FDA grants fast track designation to irinotecan liposome injection (Onivyde; MM-398) as second-line monotherapy for patients with small cell lung cancer whose disease progressed following a platinum-based chemotherapy regimen.

Investigators hope discovery will lead to new treatments for pancreatic cancer.

Pralsetinib (Gavreto) approved for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer.

Medicaid expansion was associated with a 2% drop in cancer mortality, a recent study found.